CN117717486A - Composition containing ectoine and 2' -fucosyllactose and application thereof - Google Patents
Composition containing ectoine and 2' -fucosyllactose and application thereof Download PDFInfo
- Publication number
- CN117717486A CN117717486A CN202311644456.7A CN202311644456A CN117717486A CN 117717486 A CN117717486 A CN 117717486A CN 202311644456 A CN202311644456 A CN 202311644456A CN 117717486 A CN117717486 A CN 117717486A
- Authority
- CN
- China
- Prior art keywords
- fucosyllactose
- ectoin
- composition
- retinol
- mass ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HWHQUWQCBPAQQH-BWRPKUOHSA-N 2-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O HWHQUWQCBPAQQH-BWRPKUOHSA-N 0.000 title claims abstract description 63
- 229940062827 2'-fucosyllactose Drugs 0.000 title claims abstract description 62
- HWHQUWQCBPAQQH-UHFFFAOYSA-N 2-O-alpha-L-Fucosyl-lactose Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(CO)OC1OC(C(O)CO)C(O)C(O)C=O HWHQUWQCBPAQQH-UHFFFAOYSA-N 0.000 title claims abstract description 62
- SNFSYLYCDAVZGP-UHFFFAOYSA-N UNPD26986 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(O)C(O)C2O)CO)OC(CO)C(O)C1O SNFSYLYCDAVZGP-UHFFFAOYSA-N 0.000 title claims abstract description 62
- WQXNXVUDBPYKBA-YFKPBYRVSA-N ectoine Chemical compound CC1=[NH+][C@H](C([O-])=O)CCN1 WQXNXVUDBPYKBA-YFKPBYRVSA-N 0.000 title claims abstract description 50
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- WQXNXVUDBPYKBA-UHFFFAOYSA-N Ectoine Natural products CC1=NCCC(C(O)=O)N1 WQXNXVUDBPYKBA-UHFFFAOYSA-N 0.000 title description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 49
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229960003471 retinol Drugs 0.000 claims abstract description 25
- 239000011607 retinol Substances 0.000 claims abstract description 25
- 235000020944 retinol Nutrition 0.000 claims abstract description 25
- 230000008591 skin barrier function Effects 0.000 claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 230000006378 damage Effects 0.000 claims abstract description 19
- 230000007794 irritation Effects 0.000 claims abstract description 19
- 230000008439 repair process Effects 0.000 claims description 7
- 239000002537 cosmetic Substances 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 3
- 239000003995 emulsifying agent Substances 0.000 claims description 3
- 239000003906 humectant Substances 0.000 claims description 3
- 239000002562 thickening agent Substances 0.000 claims description 3
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 239000000178 monomer Substances 0.000 abstract description 6
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 239000000839 emulsion Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 210000000245 forearm Anatomy 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000001153 anti-wrinkle effect Effects 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 150000004492 retinoid derivatives Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- SFRPDSKECHTFQA-ONOWFSFQSA-N [(2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenyl] propanoate Chemical compound CCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SFRPDSKECHTFQA-ONOWFSFQSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 231100000018 phototoxicity Toxicity 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 125000002523 retinol group Chemical group 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 208000024719 uterine cervix neoplasm Diseases 0.000 description 1
Abstract
The present application provides a composition comprising ectoin and 2' -fucosyllactose and its use in reducing retinol irritation, reducing the increase in the transdermal water loss value, or repairing skin barrier damage. The composition of the application comprises the ectoin and the 2 '-fucosyllactose, so that the irritation of retinol to skin can be reduced, and compared with the ectoin and the 2' -fucosyllactose which are monomers, the composition has obvious difference in a statistical sense, and the composition has synergistic effect, so that the damage of skin barrier can be obviously improved.
Description
Technical Field
The application belongs to the technical field of cosmetics, and particularly relates to a composition containing ectoine and 2' -fucosyllactose and application thereof in reducing retinol irritation, reducing increase of percutaneous water loss value or repairing skin barrier injury.
Background
The retinoid acid compound is a vitamin a derivative and comprises two sources of natural and synthetic, and has wide biological application prospects, including cancer treatment, cervical tumor and the like, wherein the most prominent application direction is skin disease treatment, and the treatment of actinic keratosis, psoriasis and ichthyosis has been reported since 1940s is used for acne treatment for the first time. Subsequently, retinoid substances, which mainly include retinol, retinol palmitate, retinol propionate, retinol acetate and the like, are increasingly used in the cosmetic field for anti-wrinkle efficacy. Although the above-mentioned substances have excellent anti-wrinkle effects, the irritation to the skin is not neglected, common irritation after application includes stinging, erythema, burning, allergy, and the like, and phototoxicity generated by decomposition through ultraviolet irradiation also causes strong irritation. The direct impact of these skin problems is an impaired skin barrier, such as an increased percutaneous water loss (TEWL) value, and a reduced expression of associated barrier-associated proteins.
Retinol is favored by consumers as a powerful anti-wrinkle ingredient in cosmetics, but is limited in application process because of great irritation to skin, causing problems of skin allergy, redness, stinging and the like, and further causing damage to skin barrier.
Disclosure of Invention
In response to the problems of the prior art, the present application provides a composition comprising ectoin and 2' -fucosyllactose and its use in reducing retinol irritation, reducing the increase in the percutaneous water loss value or repairing skin barrier damage.
In particular, the present application relates to the following:
1. a composition comprising ectoin and 2' -fucosyllactose.
2. The composition according to item 1, wherein the mass ratio of the exendin to the 2' -fucosyllactose is (0.01-20): 1
3. The composition according to item 1 or 2, wherein the mass ratio of exendin to 2' -fucosyllactose is (0.1-17): 1.
4. The composition according to any one of claims 1 to 3, wherein in the composition, the content of ectoin is 0.05wt% to 5wt%, and the content of 2' -fucosyllactose is 0.05wt% to 4wt%.
5. The composition of any one of claims 1-4, further comprising retinol.
6. The composition of item 5, wherein the composition further comprises one or more of a humectant, an emulsifier, a thickener, a pH adjustor, and a chelating agent.
7. Use of the composition of any one of items 1-4 to reduce retinol irritation, reduce the increase in transdermal water loss value, and/or repair skin barrier damage.
8. The use according to item 7, wherein the increase in the percutaneous water loss value is an increase in the percutaneous water loss value caused by retinol, and the skin barrier damage is a repair of a retinol-caused skin barrier damage.
9. Use of a combination of ectoin and 2' -fucosyllactose to reduce retinol irritation, reduce the increase in the transdermal water loss value and/or repair skin barrier damage.
10. The use according to item 9, wherein the increase in the percutaneous water loss value is an increase in the percutaneous water loss value caused by retinol, and the skin barrier damage is a repair of a retinol-caused skin barrier damage.
11. The use according to item 9 or 10, wherein the mass ratio of ectoin to 2' -fucosyllactose is (0.01-20): 1.
12. The use according to item 9 or 10, wherein the mass ratio of ectoin to 2' -fucosyllactose is (0.1-17): 1.
The composition of the application comprises the ectoin and the 2 '-fucosyllactose, so that the irritation of retinol to skin can be reduced, and compared with the ectoin monomer and the 2' -fucosyllactose monomer, the composition has obvious difference in a statistical sense, and the composition has synergistic effect, so that the damage of skin barrier can be obviously improved.
Drawings
FIG. 1 shows the TEWL differences for each monomer and different blend compositions.
Detailed Description
The present application is further illustrated below with reference to examples, it being understood that the examples are for further illustration and explanation of the application only and are not intended to limit the application.
Unless defined otherwise, technical and scientific terms used in this specification have the same meaning as commonly understood by one of ordinary skill in the art. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the materials and methods are described herein below. In case of conflict, the present specification, including definitions therein, will control and materials, methods, and examples, will control and be in no way limiting. The present application is further illustrated below in conjunction with specific examples, but is not intended to limit the scope of the present application.
The present application provides a composition comprising ectoin and 2' -fucosyllactose.
In a specific embodiment, in the irritation-reducing composition, the mass ratio of ectoin to 2-fucosyllactose is from (0.01 to 20): 1, the number of the components is 1, for example, 0.5:1:0:1:0.5:1:1:0:1:1:0:1:1:5:0:1:6:6:6:6:0:6:6:6:6:6:6:6:1:6:6:6:1:6:6:1:6:1:6:6:1:6:1:6:1:6:1:1:3:1:1:1:1:3:1:1:1:1:2:1:1:1:1:1:2:1:1:2:1:1:3:3:3:3:3:3:3:3:3:3:1:1:1:1:1:1:1:2:1:1:2:3:3:3:3:3:3:3:1:1:1:2:1:1:3:1:2:1:2:3:5:3:2:5:3:3:5:3:1:5:3:3:5:5:3:3:2:5:3:3:5:3:3:5:3:2:2:2:2:2:2:2:2:2:2:2:2::::::::::::2:2::::::::::and:2:2:2:2:2:and:and:and:and:2:and:2:and:and:and:and:and:and:and:and:and:and:and:and:and:and:and:and:and:and:and:and:and:and:and:and:and:and:and:and:and:and:and:and:and:and:and or and or and or or and or or or:or:or or or or:or or or:or:or:or:or:or:or:or:or:or:or:or:or:or:or::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: and any range between these values.
In a specific embodiment, the mass ratio of ectoin to 2' -fucosyllactose in the composition is (0.1-17): 1.
In a specific embodiment, the content of the ectoin in the composition is 0.05wt% to 5wt%, for example, it may be 0.05wt%, 0.06wt%, 0.07wt%, 0.08wt%, 0.09wt%, 0.1wt%, 0.2wt%, 0.3wt%, 0.4wt%, 0.5wt%, 0.6wt%, 0.7wt%, 0.8wt%, 0.9wt%, 1wt%, 1.1wt%, 1.2wt%, 1.3wt%, 1.4wt%, 1.5wt%, 1.6wt%, 1.7wt%, 1.8wt%, 1.9wt%, 2wt%, 2.1wt%, 2.2wt%, 2.3wt%, 2.4wt%, 2.5wt%, 2.6wt%, 2.7wt%, 2.8wt%, 2.9wt%, 3wt%, 3.1wt%, 3.2wt%, 3.3wt%, 3.4wt%, 3.5wt%, 3.6wt%, 3.7wt%, 3.8wt%, 3.9wt%, 4.1wt%, 4.2wt%, 4.3wt%, 4.4wt%, 4.5wt%, and any of these ranges; the content of 2' -fucosyllactose is 0.05wt% to 4wt%, and may be, for example, 0.05wt%, 0.06wt%, 0.07wt%, 0.08wt%, 0.09wt%, 0.1wt%, 0.2wt%, 0.3wt%, 0.4wt%, 0.5wt%, 0.6wt%, 0.7wt%, 0.8wt%, 0.9wt%, 1wt%, 1.1wt%, 1.2wt%, 1.3wt%, 1.4wt%, 1.5wt%, 1.6wt%, 1.7wt%, 1.8wt%, 1.9wt%, 2wt%, 2.1wt%, 2.2wt%, 2.3wt%, 2.4wt%, 2.5wt%, 2.9wt%, 3wt%, 3.1wt%, 3.2wt%, 3.3wt%, 3.4wt%, 3.5wt%, 3.6wt%, 3.7wt%, 3.8wt%, 3.9wt%, and any range between these ranges.
In a specific embodiment, the mass ratio of the ectoin to the 2 '-fucosyllactose in the composition is (0.01-20): 1, the ectoin content is 0.05-5 wt%, and the 2' -fucosyllactose content is 0.05-4 wt%.
In a specific embodiment, the mass ratio of the ectoin to the 2 '-fucosyllactose in the composition is (0.1-17): 1, the ectoin content is 0.05wt% to 5wt%, and the 2' -fucosyllactose content is 0.05wt% to 4wt%.
It will be appreciated by those skilled in the art that the compositions of the present application may further comprise other ingredients, such as solvents or other excipients, in addition to the exendin and 2' -fucosyllactose.
In a specific embodiment, the irritation reducing composition consists of ectoin and 2' -fucosyllactose.
In a specific embodiment, the irritation reducing composition consists of ectoin and 2' -fucosyllactose in a mass ratio of (0.01-20): 1.
In a specific embodiment, the irritation reducing composition comprises of ectoin and 2' -fucosyllactose in a mass ratio of (0.1-17): 1.
A composition of any of the above, further comprising retinol.
One skilled in the art will appreciate that the composition may further comprise one or more of a humectant, an emulsifier, a thickener, a pH modifying agent, a chelating agent.
The present application also provides the use of any of the above compositions for reducing retinol irritation.
The present application also provides the use of any of the above compositions for reducing the increase in the transdermal water loss value.
Further, the percutaneous water loss value is a retinol-induced percutaneous water loss value.
The present application also provides the use of any of the above compositions in the repair of skin barrier damage.
Further, the skin barrier damage is retinol-induced skin barrier damage.
In the present application, the percutaneous Water loss (TEWL) value is measured by methods and apparatus known in the art, e.g., CK, germanyTM Hex or related instrument. The principle of Tewameter to determine TEWL value derives from Fick's law of diffusion:
dm/dt- -the amount of water evaporated per hour, D- -the diffusion constant, A- -the test area, dp/dx- -the pressure difference between the upper and lower sensors, mmHg.
The present application also provides the use of a combination of ectoin and 2' -fucosyllactose to reduce retinol irritation.
In a specific embodiment, the mass ratio of ectoin to 2' -fucosyllactose in said use is (0.01-20): 1.
In a specific embodiment, the mass ratio of ectoin to 2' -fucosyllactose in said use is (0.1-17): 1.
The present application also provides the use of a combination of ectoin and 2' -fucosyllactose to reduce the increase in the transdermal moisture loss value.
In a specific embodiment, the mass ratio of ectoin to 2' -fucosyllactose in said use is (0.01-20): 1.
In a specific embodiment, the mass ratio of ectoin to 2' -fucosyllactose in said use is (0.1-17): 1.
The present application also provides the use of a combination of ectoin and 2' -fucosyllactose in repairing skin barrier lesions.
In a specific embodiment, the mass ratio of ectoin to 2' -fucosyllactose in said use is (0.01-20): 1.
In a specific embodiment, the mass ratio of ectoin to 2' -fucosyllactose in said use is (0.1-17): 1.
The composition of the application can effectively reduce the irritation of retinol to skin by combining the ectoin and the 2 '-fucosyllactose, especially combining the ectoin and the 2' -fucosyllactose in a specific mass ratio, for example, combining the ectoin and the 2 '-fucosyllactose in a mass ratio of (0.01-20): 1, and has obvious difference in statistical sense relative to the monomer ectoin and the monomer 2' -fucosyllactose, which indicates that the combination has synergistic effect and can obviously improve the damage of skin barrier.
Examples
The reagents and apparatus used in the examples and comparative examples of the present application are shown in table 1.
TABLE 1
Example 1
The composition comprises 0.91g of 2' -fucosyllactose and 0.09g of ectoin, and the preparation method comprises the following steps:
0.35g of carbomer U20 was weighed into a 200mL beaker, then 0.91g of 2' -fucosyllactose powder, 0.09g of ectoin, 7.5g of glycerol and 0.1g of disodium ethylenediamine tetraacetate were weighed into the beaker, and a certain amount of deionized water was continuously added into the beaker, and stirred at 75℃to 80℃to obtain phase A. 0.5g of p-hydroxyacetophenone and 0.5g of 1, 2-hexanediol are weighed into a small beaker and stirred under heating at 60-70 ℃ until completely dissolved, thus obtaining phase B. 10g of retinol and 0.5g of LRI (PEG-40 hydrogenated castor oil, PPG-26 butanol polyether 26) are weighed, heated and stirred at 75-80 ℃ until dissolved, to obtain phase C. Adding the phase C into the phase A under the heating condition of 75-80 ℃, dispersing for 5-10 min by a dispersing machine, cooling to about 40 ℃, adding the phase B into the mixed solution, and regulating the pH of the system to about 6.1 by adopting a 1% NaOH aqueous solution to obtain emulsion. The mass of the emulsion finally obtained was 100g.
Examples 2 to 8
Examples 2-8 differ from example 1 only in the amounts of added exendin and 2 '-fucosyllactose, but the total amounts of exendin and 2' -fucosyllactose are the same. Wherein, in example 2, the amount of exendin was 0.5g and the amount of 2' -fucosyllactose was 0.5g. In example 3, the amount of exendin was 0.83g and the amount of 2' -fucosyllactose was 0.17g. In example 4, the amount of exendin was 0.94g and the amount of 2' -fucosyllactose was 0.06g. In example 5, the amount of exendin was 0.01g and the amount of 2' -fucosyllactose was 0.99g. In example 6, the amount of exendin was 0.95g and the amount of 2' -fucosyllactose was 0.05g. In example 7, the amount of exendin was 0.9444g and the amount of 2' -fucosyllactose was 0.0556g. In example 8, the amount of exendin was 0.9474g and the amount of 2' -fucosyllactose was 0.0526g.
Comparative example 1
Comparative example 1 differs from example 1 only in that no ectoin and no 2' -fucosyllactose were added.
Comparative example 2
Comparative example 2 differs from example 1 only in that 2' -fucosyllactose was not added and that the addition amount of exendin was 1g.
Comparative example 3
Comparative example 3 differs from example 1 only in that no ectoin was added and that 2' -fucosyllactose was added in an amount of 1g.
The contents of the respective components in the above examples and comparative examples are shown in Table 2.
TABLE 2
Test examples
In the test example, firstly, retinol and active substances are simultaneously added into basic emulsion at the inner side of the forearm of a human body, a barrier damage model is manufactured by continuously using an emulsion sample, and after the model is successfully manufactured, the change of TEWL (test wl) of each smearing part is monitored, wherein the increase of the TEWL value represents the increase of percutaneous water loss, which indicates that the barrier function is damaged; a decrease in TEWL value represents a decrease in transdermal water loss, indicating skin barrier repair. Since the TEWL values are different for each different part of the skin, background effects are subtracted by calculating the TEWL difference by subtracting the pre-use TEWL value from the post-use TEWL value and comparing the tewil difference to account for the significance of the differences between groups.
(1) Screening of retinol sensitive populations
1g of emulsion sample containing retinol only (i.e. the sample of comparative example 1) was applied to the forearm of the subject, and the application was performed uniformly for 20 times, 1 time each in the morning and at night, and 2 days in succession, subjects with tingling, burning and pain feedback were selected, wherein 8 subjects satisfying the standard were selected in total, 8 women were aged 21 to 31 years, and the average age was 25.88.+ -. 1.17 years.
(2) TEWL test
Firstly, the inner side of the forearm of a subject is washed by clean water, wiped clean by paper towels, and is kept for 30min in a constant temperature and constant humidity environment (the temperature is 20-22 ℃ and the humidity is 40-60%). The inner sides of the 2 forearms of the subjects were each scored into 10 square areas, each area 1.5cm x 1.5cm in size. Then useTM Hex test pre-sample TEWL values were applied to each area, 1g of the different samples of examples 1-8 and comparative examples 2-3, respectively, were applied in circles 20 times until complete absorption, each time in the morning and evening, 2 consecutive days, and day 3 to test each area TEWL value.
The collected data are collated and the variability is analyzed by statistical methods. The test results are shown in table 3 and fig. 1, where x represents statistically significant differences (p < 0.05) from monomeric ectoin comparison, and from monomeric 2' -fucosyllactose comparison, consistent with the above trend, both statistically significant differences (p < 0.05).
TABLE 3 Table 3
Claims (10)
1. A composition comprising ectoin and 2' -fucosyllactose.
2. The composition according to claim 1, wherein the mass ratio of ectoin to 2' -fucosyllactose is (0.01-20): 1.
3. The composition according to claim 1 or 2, wherein the mass ratio of ectoin to 2' -fucosyllactose is (0.1-17): 1.
4. A composition according to any one of claims 1-3, wherein in the composition the content of ectoin is 0.05-5 wt%, and the content of 2' -fucosyllactose is 0.05-4 wt%.
5. The composition of any one of claims 1-4, wherein the composition further comprises retinol.
6. The composition of claim 5, wherein the cosmetic further comprises one or more of a humectant, an emulsifier, a thickener, a pH adjuster, a chelating agent.
7. Use of the composition of any one of claims 1-6 for reducing retinol irritation, reducing the increase in transdermal water loss value, and/or repairing skin barrier damage.
8. Use of a combination of ectoin and 2' -fucosyllactose to reduce retinol irritation, reduce the increase in the transdermal water loss value and/or repair skin barrier damage.
9. The use according to claim 8, wherein the mass ratio of ectoin to 2' -fucosyllactose is (0.01-20): 1.
10. The use according to claim 8 or 9, wherein the mass ratio of ectoin to 2' -fucosyllactose is (0.1-17): 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311644456.7A CN117717486A (en) | 2023-12-04 | 2023-12-04 | Composition containing ectoine and 2' -fucosyllactose and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311644456.7A CN117717486A (en) | 2023-12-04 | 2023-12-04 | Composition containing ectoine and 2' -fucosyllactose and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117717486A true CN117717486A (en) | 2024-03-19 |
Family
ID=90202638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311644456.7A Pending CN117717486A (en) | 2023-12-04 | 2023-12-04 | Composition containing ectoine and 2' -fucosyllactose and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117717486A (en) |
-
2023
- 2023-12-04 CN CN202311644456.7A patent/CN117717486A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080249064A1 (en) | Activities of an active principle obtained from powdered alfalfa seeds (Medicago sativa), active principle used and process of obtaining the same | |
| JP2000319157A (en) | Skin lotion | |
| DE102008059523A1 (en) | Cosmetic mixture containing ascorbic acid-2-glucoside and ergothioneine | |
| JP6138361B2 (en) | Topical formulation containing grape seed, folic acid, biotin, Bifidobacterium longum and echinacea purpurea | |
| EP1569724B1 (en) | Formulations containing melatonin, ginkgo biloba, and biotin | |
| US20160128924A1 (en) | Composition for Improving Skin Condition Containing a Vitamin Mixture | |
| DE69830397T2 (en) | USE OF AN ADANSONIA GENUS EXTRACT | |
| CN112656709A (en) | Skin care compositions and uses thereof | |
| DE69829838T2 (en) | PROCESS FOR STABILIZING LEFT-ROTATING ASCORBIC ACID (LAA) AND STABLE COMPOSITIONS OF LAA | |
| KR102463131B1 (en) | Composition containing aha, urea, and niacinamide for softening and whitening stratum corneum | |
| CN112315883B (en) | Skin care composition for controlling oil and removing acne and preparation and application thereof | |
| WO2022087666A1 (en) | Retinol compositions, methods of their preparation and use | |
| CN109568159A (en) | Cosmetic composition and its preparation method and application is repaired in a kind of whitening | |
| JP2001122758A (en) | COSMETIC FOR PROTECTING AND IMPROVING AGED SKIN HAVING AGEs DEGRADING ACTIVITY | |
| CN117717486A (en) | Composition containing ectoine and 2' -fucosyllactose and application thereof | |
| CN106361595A (en) | Zhiyan introduced solvent essence | |
| CN117717485A (en) | Composition containing ectoine and raffinose and application thereof | |
| EP1731532A1 (en) | Depolymerised scleroglucan for the regulation and improvement of the moisture content of the skin | |
| CN115487110A (en) | Composition with anti-aging effect and preparation method and application thereof | |
| CN107496248A (en) | A kind of net white composition and the skin care item containing said composition | |
| CN111821219A (en) | Composition with moisturizing effect and application thereof | |
| KR101296153B1 (en) | Cosmetic composition for pore-minimizing using scoria | |
| CN106456596B (en) | Tea water without catechin and composition containing the same | |
| JP3367621B2 (en) | Cosmetic for wrinkle improvement | |
| JP6973740B1 (en) | Skin beauty composition and skin beauty method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |